CYT 108
Alternative Names: A2M - Cytonics; Cyt-108; CYT108; Recombinant A2M - Cytonics; α-2 macroglobulin - Cytonics; α2M - CytonicsLatest Information Update: 14 Apr 2025
At a glance
- Originator Cytonics Corporation
- Class Antirheumatics; Foot disorder therapies; Recombinant proteins
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Osteoarthritis
Highest Development Phases
- Phase I Osteoarthritis
- No development reported Diabetic foot ulcer